Concepedia

Author

Kevin Smart

GlaxoSmithKline (United Kingdom)

Also Known As

K Smart, K. Smart, Kevin A. Smart, Kevin Smart, Klint Smart, Kyla Smart

42

Publications

566

Citations

10

H-Index

11

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Roche (United Kingdom)Roche (Switzerland)Princess Margaret Cancer CentreRoche Pharma AG (Germany)
KS

About

Kevin Smart is an author at GlaxoSmithKline (United Kingdom) specializing in immunology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

193

2

Immunology

2

2

193

3

Allergy

1

1

178

4

Pharmacology

1

1

15

5

Asthma

1

1

178

Kevin Smart

×

11

Publications

516

Citations

10

H-Index

YearCitations

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial

Saifudin Khalid, Robert Murdoch, Amy Newlands,

Journal of Allergy and Clinical Immunology

2014

178

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau,

Clinical Cancer Research

2017

99

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

Bruce E. Miller, Sunil Mistry, Kevin Smart,

BMC Pharmacology and Toxicology

2015

63

The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis

Philippe Bareille, Robert Murdoch, Jane Denyer,

International Journal of Clinical Pharmacology and Therapeutics

2013

40

Inhibition of capsaicin‐driven nasal hyper‐reactivity by <scp>SB</scp>‐705498, a <scp>TRPV</scp>1 antagonist

Carlijn Holland, Cornelis M. van Drunen, Jane Denyer,

British Journal of Clinical Pharmacology

2013

31

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

Richard Follows, Neil G. Snowise, Shuyen Ho,

Respiratory Research

2013

29

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

Bruce E. Miller, Kevin Smart, Sunil Mistry,

European Journal of Drug Metabolism and Pharmacokinetics

2014

19

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

Kevin Smart, Ann-Marie E Bröske, Dominik Rüttinger,

Clinical Pharmacology & Therapeutics

2020

18

291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors

Fabrice Barlési, Martijn P. Lolkema, Kristoffer Staal Rohrberg,

Regular and Young Investigator Award Abstracts

2020

15

TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis

Robert Murdoch, Philippe Bareille, Jane Denyer,

International Journal of Clinical Pharmacology and Therapeutics

2014

14

Page 1